Total Payments
$27,090
2024 Payments
$4,775
Companies
76
Transactions
1,419
Medicare Patients
15,003
Medicare Billing
$4.3M
Payment Breakdown by Category
Food & Beverage$21,836 (80.6%)
Consulting$2,850 (10.5%)
Education$1,870 (6.9%)
Travel$330.06 (1.2%)
Other$205.00 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $21,836 | 1,371 | 80.6% |
| Consulting Fee | $2,850 | 4 | 10.5% |
| Education | $1,870 | 36 | 6.9% |
| Travel and Lodging | $330.06 | 2 | 1.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $205.00 | 6 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Heron Therapeutics, Inc. | $3,047 | 6 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $2,673 | 175 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,603 | 99 | $0 (2024) |
| Janssen Biotech, Inc. | $1,462 | 78 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,364 | 76 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,295 | 95 | $0 (2024) |
| PFIZER INC. | $1,186 | 92 | $0 (2024) |
| Amgen Inc. | $1,171 | 90 | $0 (2023) |
| Astellas Pharma US Inc | $933.57 | 23 | $0 (2023) |
| Celgene Corporation | $898.21 | 62 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,775 | 244 | E.R. Squibb & Sons, L.L.C. ($482.53) |
| 2023 | $4,796 | 226 | Stemline Therapeutics Inc. ($404.39) |
| 2022 | $1,015 | 47 | Astellas Pharma US Inc ($233.13) |
| 2021 | $1,805 | 110 | E.R. Squibb & Sons, L.L.C. ($365.83) |
| 2020 | $1,075 | 61 | E.R. Squibb & Sons, L.L.C. ($153.21) |
| 2019 | $3,515 | 232 | E.R. Squibb & Sons, L.L.C. ($501.53) |
| 2018 | $3,644 | 241 | Novartis Pharmaceuticals Corporation ($315.92) |
| 2017 | $6,465 | 258 | Heron Therapeutics, Inc. ($3,047) |
All Payment Transactions
1,419 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $31.69 | General |
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $25.47 | General |
| Category: Oncology | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/15/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $10.43 | General |
| Category: Oncology | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $29.20 | General |
| 12/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.20 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Oncology | ||||||
| 12/05/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $15.12 | General |
| 12/03/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $27.20 | General |
| Category: Hematology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Oncology | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $28.88 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Oncology | ||||||
| 11/25/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Oncology | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Oncology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Amneal Pharmaceuticals LLC | AVASTIN (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: Oncology | ||||||
| 11/13/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 49 | 3,092 | 172,303 | $3.2M | $830,692 |
| 2022 | 58 | 3,746 | 201,276 | $3.4M | $967,720 |
| 2021 | 59 | 3,785 | 173,651 | $3.3M | $1.1M |
| 2020 | 68 | 4,380 | 280,707 | $4.5M | $1.5M |
Total Patients
15,003
Total Services
827,937
Medicare Billing
$4.3M
Procedure Codes
234
All Medicare Procedures & Services
234 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 36 | 11,820 | $839,220 | $218,185 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 379 | 1,701 | $297,675 | $151,788 | 51.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 25 | 36,300 | $435,600 | $85,313 | 19.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 47 | 95,250 | $381,000 | $83,555 | 21.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 13 | 696 | $418,992 | $68,535 | 16.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 44 | 50 | $110,500 | $54,202 | 49.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 41 | 411 | $172,620 | $38,346 | 22.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 360 | 1,779 | $21,348 | $14,916 | 69.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 105 | 324 | $42,768 | $14,681 | 34.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 41 | 580 | $38,860 | $12,083 | 31.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 343 | 1,492 | $46,252 | $11,341 | 24.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 83 | 104 | $22,880 | $9,847 | 43.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 270 | 798 | $32,718 | $8,242 | 25.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 55 | 55 | $14,850 | $6,672 | 44.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 46 | 53 | $47,011 | $6,453 | 13.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 89 | 488 | $24,400 | $4,905 | 20.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 16 | 103 | $28,737 | $4,841 | 16.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 79 | $9,322 | $4,609 | 49.4% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 241 | 518 | $12,950 | $4,294 | 33.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 22 | 180 | $23,220 | $3,728 | 16.1% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 26 | 27 | $14,715 | $3,539 | 24.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 13 | 15 | $10,860 | $2,564 | 23.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 136 | $5,848 | $1,967 | 33.6% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 18 | 22 | $13,420 | $1,737 | 12.9% |
| 77067 | Screening mammography | Office | 2023 | 20 | 20 | $4,900 | $1,705 | 34.8% |
About Dr. Ahsanul Haque, M.D
Dr. Ahsanul Haque, M.D is a Hematology & Oncology healthcare provider based in Elkhart, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558364372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ahsanul Haque, M.D has received a total of $27,090 in payments from pharmaceutical and medical device companies, with $4,775 received in 2024. These payments were reported across 1,419 transactions from 76 companies. The most common payment nature is "Food and Beverage" ($21,836).
As a Medicare-enrolled provider, Haque has provided services to 15,003 Medicare beneficiaries, totaling 827,937 services with total Medicare billing of $4.3M. Data is available for 4 years (2020–2023), covering 234 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Elkhart, IN
- Active Since 05/24/2005
- Last Updated 01/15/2026
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1558364372
Products in Payments
- SUSTOL (Drug) $3,047
- KEYTRUDA (Biological) $1,336
- OPDIVO (Biological) $1,143
- ZEJULA (Drug) $622.43
- XARELTO (Drug) $592.82
- IMBRUVICA (Drug) $523.64
- IBRANCE (Drug) $484.30
- Lenvima (Drug) $479.17
- JEVTANA (Drug) $460.36
- Orserdu (Drug) $443.04
- VERZENIO (Drug) $416.67
- ELIQUIS (Drug) $404.31
- DARZALEX (Biological) $387.54
- Pomalyst (Drug) $359.69
- KISQALI (Drug) $356.81
- Imbruvica (Drug) $314.27
- Kyprolis (Biological) $301.09
- TAGRISSO (Drug) $274.16
- CABOMETYX (Drug) $271.82
- Enhertu (Drug) $270.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.